Latest from Rutgers Cancer Institute of New Jersey

Advanced SCCS continues to be a treatment challenge given the aggressive behavior of a subset of cases and the absence of randomized clinical trials to provide guidelines for therapy.
ORIEN partnership founded by The Ohio State University Comprehensive Cancer Center and Moffitt Cancer Center adds three new members, widens patient access to precision clinical trials.
Howard L. Kaufman, MD, discusses the rapidly advancing immunotherapy armamentarium in melanoma.
At a recent FDA joint advisory committee meeting, members voted 22-1 to recommend approval of the oncolytic immunotherapy talimogene laherparepvec as a treatment for patients with advanced melanoma.
The field of prostate cancer vaccines remains an area of active exploration, with clinical trials into sipuleucel-T continuing even amid a corporate restructuring and a phase III study into PROSTVAC reaching full enrollment.
In this segment, the panel members share their thoughts on use of checkpoint inhibitors for first-line treatment of advanced melanoma.
An improved understanding of how the immune system recognizes and eradicates cancer cells, along with advances in drugs that effectively promote antitumor immune responses, is revolutionizing the field of cancer therapy.
Stuart L. Goldberg, MD, describes how to select the best candidates for ponatinib.
Publication Bottom Border
Border Publication